Rapidly Dispersible Dosage Form of Oxcarbazepine

ABSTRACT

A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.

CROSS-REFERENCE TO EARLIER FILED APPLICATIONS

The present application claims the benefit of and is a continuation ofapplication Ser. No. 14/837,493 filed Aug. 27, 2015, which is acontinuation of application No. PCT/US2014/028125 filed Mar. 14, 2014,which claims the benefit of provisional application No. 61/791,726 filedMar. 15, 2013, the entire disclosures of which are hereby incorporatedby reference.

FIELD OF THE INVENTION

The present invention concerns a rapidly dispersing (orodispersible)solid oral dosage form of oxcarbazepine. In particular, the dosage formdisperses within a period of less than about ten seconds when placed inthe mouth of a subject. The invention also relates to methods of use ofthe dosage form for the treatment of diseases, disorders or conditionsthat are therapeutically responsive to oxcarbazepine or a derivativethereof. A process for preparing the dosage form is also provided.

BACKGROUND OF THE INVENTION

Solid oral dosage forms containing oxcarbazepine (OXC;10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide; disclosed inU.S. 2004-0044200A1, U.S. Pat. No. 3,642,775 and U.S. Pat. No.3,716,640) are known (FDA Electronic Orange Book). OXC is susceptible tohydrolysis under basic/alkaline conditions. Oxcarbazepine is a prodrugthat is quickly reduced to a 10-monohydroxy metabolite derivative (MHD)which is the active metabolite.

OXC is an antiepileptic indicated for use as monotherapy or adjunctivetherapy in the treatment of partial seizures in adults and asmonotherapy in the treatment of partial seizures in children aged 4years and above with epilepsy, and as adjunctive therapy in childrenaged 2 years and above with epilepsy.

OXC is hydrophobic and poorly water soluble and must be present in verysmall particles sizes when administered as a solid oral dosage form inorder to provide sufficient absorption of drug. U.S. Pat. No. 7,037,525specifies oxcarbazepine having a particle size such that the maximumresidue on a 40 micron sieve is less than or equal to 5% and the medianparticle size is approximately 2 to 12 microns, or 4 to 10 microns or 6to 8 microns. EP 2,010,499 A1 discloses oxcarbazepine having a particlesize distribution with a D[v,0.5] value of between about 15 microns toabout 30 microns and a D[v,0.9] value of less than or equal to 90microns. U.S. Pat. No. 8,119,148 discloses OXC wherein the quantity ofparticles larger than 40 micrometers (μm) is limited to a maximum of 5%by weight and the median particle size by Fraunhofer diffraction isspecified to be within 4-10 μm. EP 2,077,822 discloses OXC with a medianparticle size of 4-10 PCT Publication WO 2007-007182 discloses OXC witha median particle size in the range of 15 to 30 μm and wherein thecomposition contains no wetting agent. PCT Publication WO 2006-046105discloses OXC with a median particle size in the range of 15 to 30 μmand wherein the composition contains no wetting agent. PCT PublicationWO 2002-094774 discloses OXC with a median particle size of about 20 μmto about 50 μm with a maximum residue of about 10% on a 45 μm to up to100 μm sieve and wherein a wetting agent is present. Indian ApplicationNo. 1186/MUM/2004 discloses a pharmaceutical composition containingoxcarbazepine particles and meglumine, which aids in dissolution of thedrug, wherein the oxcarbazepine has a particle size of not less than 50μm or about 80 to 140 μm. EP 2,146,699 A1 discloses dosage formscontaining oxcarbazepine having a median particle size of about 2 μm orless.

OXC is dosed orally according to a twice daily regimen (BID) at doses of300 to 2400 mg per day for the treatment of epilepsy. When a unit doseincludes 150 to 1200 mg of OXC, young and elderly patients typicallyexperience difficulty in swallowing solid oral dosage forms containingsuch high doses, especially because of the large amount of excipientsincluded in known dosage forms. Difficulty in swallowing leads to poorpatient compliance. Attempts to resolve this problem have led to thedevelopment of oral liquid formulations. Stability, contamination andinaccurate dosing problems, however, are still associated with suchdosage forms.

Given the high doses of OXC required per tablet, it is difficult toformulate rapidly dispersible solid oral dosage forms with sufficienthardness and friability suitable for storage and handling while at thesame time providing a dosage form that is small enough for easyswallowing.

Orodispersible dosage forms disperse or disintegrate in the mouth in aminimal amount of saliva or water. Such dosage forms provide ease ofswallowing, accuracy of dosing, and rapid therapeutic action. U.S. Pat.No. 7,749,533 to Fu et al. discloses a dosage form containing granulescontaining a drug, porous plastic substance, water penetration enhancer,binder and drug. The granules must be compressed in order to create thedosage form. U.S. Pat. No. 4,371,516 to Gregory et al. and U.S. Pat. No.5,738,875 disclose freeze-dried dosage forms. U.S. Pat. No. 5,178,878 toWehling et al. discloses a soft-compress orodispersible dosage form.Effervescent dosage forms and quick release coatings of insolublemicroparticles are described in U.S. Pat. Nos. 5,578,322 and 5,607,697.Freeze dried foams and liquids are described in U.S. Pat. No. 4,642,903and U.S. Pat. No. 5,631,023. Melt-spun dosage forms are described inU.S. Pat. Nos. 4,855,326, 5,380,473 and 5,518,730. U.S. 20070218129discloses an immediate release dispersible and orodispersible solidpharmaceutical composition having the form of particles with a sizelower than 710 μm upon dispersion into water, wherein the formulation ismade by wet granulation; however, the disintegration times range from 53to 60 sec.

U.S. Pat. No. 6,471,992, U.S. 2012-0207929 and U.S. 2003-0133975disclose three-dimensionally printed rapidly dispersing dosage forms.Even so, an orodispersible three-dimensionally printed dosage formcontaining OXC has not been suggested. It is not possible to predict apriori whether a three-dimensionally printed dosage form containingsubstantial amounts of OXC can be made to disperse in a minimal amountof aqueous fluid in 10 sec or less or 5 sec or less while at the sametime possessing sufficient hardness to endure handling and storage.

Very few orodispersible dosage forms containing OXC have been disclosedor suggested. U.S. Pat. No. 8,127,516 and U.S. 20120110957 to Leesuggest a film-coated tablet or film-coated powder fill. U.S. Pat. No.8,012,505 and U.S. 20040228919 to Houghton suggest a freeze-driednon-compressed fast-dispersing solid dosage form. U.S. Pat. No.6,709,669 and U.S. Pat. No. 6,509,040 to Murray and U.S. 20040076666 toGreen suggest a freeze-dried non-compressed fast-dispersing solid dosageform having fish gelatin as carrier. U.S. 20080312168 to Pilgaonkardiscloses a dispersible compressed tablet that disperses in water inthree minutes. The tablet contains oxcarbazepine, Copovidone (KollidonVA 64), microcrystalline cellulose (Avicel PH 102), Sodium starchglycolate (Primojel), Crospovidone (Kollidon CL),Hydroxypropylmethylcellulose (Methocel K100 LV), Hydroxyethylcellulose(Natrosol HHX), Aerosil, Talc and magnesium stearate.

It would be beneficial to provide a rapidly-dispersing solid oral dosageform containing a high concentration of OXC and exhibiting lowfriability and sufficient hardness to withstand storage and handlingwhile at the same time exhibiting an extremely rapid disintegration rateand acceptable taste; however, no such suitable dosage form has beensuggested in the art. In particular, no such three-dimensionally printeddosage form has been suggested.

SUMMARY OF THE INVENTION

The present invention seeks to overcome some or all of the disadvantagesinherent in the art. The present invention provides an orodispersiblesolid dosage form, as described herein, comprising oxcarbazepine as theprimary or sole active ingredient, wherein the dosage form comprises abound matrix that disperses in about 15 sec or less in a volume of about10 ml or less of water or saliva. The matrix disperses in the mouth of asubject to which it is administered, thereby facilitating swallowing andadministration.

The inventors have discovered it is very difficult to producethree-dimensionally printed rapidly-dispersing dosage forms containing ahigh weight percentage or high amount of small particle size OXC andexhibiting adequate hardness, acceptable surface texture and extremelyrapid dispersion/disintegration. Dosage forms made from bulk powdercomprising high amounts (percentages) of small native particles of OXCperform poorly; however, OXC must still be included in the dosage formin very small particle size form (as discussed above) in order to ensureadequate absorption in a subject to which it is administered.

In order to resolve this problem, the inventors have discovered that the“effective particle size” of OXC in the bulk powder must be increasedwithout increasing the “actual particle size” of the drug. Doing sopermits administration of OXC with an actual particle size suitable forabsorption and an effective particle size suitable for use in the bulkpowder of a 3DP orodispersible dosage form. The “effective particlesize” is increased by including small “native particles” of OXC in“drug-containing particles” in the bulk powder, such that thedrug-containing particles are larger in size than the native particlesof OXC.

In some aspects, the invention provides a rapidly dispersible, i.e.orodispersible, dosage form and administration thereof for the treatmentof diseases, conditions or disorders that are therapeutically responsiveto oxcarbazepine. The rapidly dispersible solid dosage form comprises aporous three-dimensionally printed bound orodispersible matrixcomprising drug-containing particles of OXC and bulk material comprisingat least one disintegrant, at least one surfactant, and at least onebinder. The bulk material may further comprise at least one glidant, atleast one sweetener and/or at least one flavorant.

The matrix is formed by deposition of a printing fluid to a powder,whereby the particles of the powder become bound by binder. The matrixis porous with a defined overall bulk density, disintegration(dispersion) time in aqueous fluid, dissolution time in aqueous fluid,and moisture content. The matrix provides a balance of sufficienthardness, low friability and extremely rapid dispersion time in a smallvolume of aqueous liquid.

In some embodiments, OXC is present in crystalline form. All polymorphsthereof are contemplated. The crystallinity of OXC or any other materialcan be determined by differential scanning calorimetry (DSC) todetermine the presence of amorphous material. In some embodiments, OXCis present in amorphous form in the bulk powder or in the matrix.

The invention also provides an orodispersible dosage form comprising athree-dimensionally printed matrix comprising bound sweetener, binder,disintegrant, surfactant, and drug-containing particles of OXC, whereinthe binder binds the matrix. The matrix is generally not bound by OXCitself. The printing fluid does not dissolve any substantial amount ofOXC during a three-dimensional printing process.

One aspect of the invention provides an orodispersiblethree-dimensionally printed matrix comprising: OXC, at least onesweetener, at least one binder, at least one disintegrant, at least onesurfactant, and at least one glidant; wherein the matrix comprisesparticles bound by binder; the matrix is porous and non-compressed; thematrix disperses in less than 15 sec in a volume of 15 ml of aqueousfluid; OXC is included in drug-containing particles comprising smallparticles of OXC and at least one pharmaceutical excipient as carrier;and the content of OXC in the matrix ranges from 35-60% wt based uponthe total weight of the matrix.

Some embodiments of the invention include those wherein: a) the at leastone surfactant is present in an amount ranging from 0.5-7.0% wt basedupon the final weight of the dosage form; b) the at least one sweeteneris present in an amount range from 0.01-2.0% based upon the final weightof the dosage form; c) the at least one binder is present in an amountrange from 5-15% based upon the final weight of the dosage form; d) theat least one disintegrant is present in an amount range from 10-30%based upon the final weight of the dosage form; and/or e) the at leastone glidant is present in an amount range from 0-2% based upon the finalweight of the dosage form.

Some embodiments of the invention include those wherein: a) the hardnessof the matrix ranges from about 1 to about 7 kiloponds (kp), about 1 toabout 3 kp; b) the matrix disperses in 10 sec or less when placed in 15ml of water or in saliva; c) binder is introduced into the matrix by wayof printing fluid used to form the matrix; d) binder is introduced intothe matrix by way of bulk powder used to form the matrix; e) the matrixcomprises about 150 mg to about 600 mg of OXC; f) the matrix comprises10 to 40 printed incremental layers; g) the thickness (height) of anincremental layer ranges from 0.006 to 0.014 inches or 0.008 to 0.012inches; h) the matrix is porous and non-compressed.

The drug-containing particles comprise OXC and at least one, at leasttwo, at least three, at least four, or at least five pharmaceuticalexcipients. In some embodiments, the drug-containing particles compriseOXC, at least one binder, at least one surfactant, and at least onedisintegrant. The drug-containing particles may further comprisesweetener and/or flavorant. In some embodiments, the drug-containingparticles comprise OXC, at least two binders, at least one surfactant,and at least one disintegrant.

Some embodiments of the invention include those wherein: a) content ofdrug-containing particles in the matrix generally ranges from 55-85% wt,60-80% wt or 65-70% wt based upon the total weight of matrix in thefinal dosage form; b) the drug-containing particles comprisedisintegrant, binder, surfactant and native particles of OXC; c) thecontent of native particles of OXC in the drug-containing particlesranges from 55-85% wt, 60-80% wt or 65-70% wt, based upon the finalweight of the drug-containing particles; d) the content of disintegrantin the drug-containing particles ranges from 0-30%, 1-15%, or 2-5 % wt,based upon the final weight of the drug-containing particles; e) thecontent of binder in the drug-containing particles ranges from 0-10%,1-7%, or 2-5% wt, based upon the final weight of the drug-containingparticles; f) the content of surfactant in the drug-containing particlesranges from 0-10%, 1-5%, or 1.4-4.2% wt, based upon the final weight ofthe drug-containing particles; g) the drug-containing particles aremanufactured by wet granulation.

The drug-containing particles have an average, mean or median particlesize in the range of about 50 to about 400 microns, about 50 to about300 microns, about 50 to about 250 microns, about 60 to about 250microns, about 60 to about 100 microns, or about 75 to about 250microns.

In some embodiments, OXC native particles have an average, mean ormedian particle size in the range of about 1 to about 90 microns, about1 to about 75 microns, about 1 to about 50 microns, about 1 to about 30microns, about 1 to about 15 microns, about 1 to about 10 microns, about2 to about 14 microns, about 10 to about 80 microns, about 20 to about70 microns, about 20 to about 60 microns or about 30 to about 50microns. In some embodiments, OXC natives particles have a particle sizedistribution with a Dv90 of less than about 100 microns, a Dv90 of lessthan about 90 microns, a Dv90 of less than about 75 microns, a Dv90 ofless than about 50 microns, and/or have a Dv50 of less than about 75microns, a Dv50 of less than about 50 microns, a Dv50 of less than about40 microns, a Dv50 of less than about 30 microns, a Dv50 of less thanabout 20 microns, a Dv50 of less than about 10 microns, a Dv50 of lessthan about 5 microns, a Dv50 of about 1 to about 40 microns, a Dv50 ofabout 1 to about 30 microns, a Dv50 of about 1 to about 20 microns, aDv50 of about 5 to about 15 microns and/or have a Dv10 of less thanabout 30 microns, a Dv10 of less than about 20 microns, a Dv10 of lessthan about 10 microns, a Dv10 of less than about 5 microns, a Dv10 ofless than about 1 microns. All combinations of these Dv10, Dv50 and Dv90values and ranges are contemplated. The native particle sizedistribution and/or effective particle size distribution can bemono-modal, bi-modal or multi-modal. OXC can be present as a mixture oftwo or more different native drug powders each having its own nativeparticle size distribution and/or method of preparation. Thedrug-containing particles can be present as a mixture of two or moredifferent powders each having its own effective particle sizedistribution and/or method of preparation. In some embodiments, the OXCcomprises a milled first form and a micronized second form. The amountof first form can range from 0-25% wt, 10-15% wt or 13-15% wt, and theamount of second form can range 100-75% wt, 90-85% wt, or 97-85% wt,respectively.

Some embodiments of the invention include those wherein the matrixcomprises about 150 to about 1200 mg, about 150 mg, about 300 mg, about450 mg, about 600 mg, about 750 mg, about 900 mg, about 1050 mg or about1200 of OXC.

The matrix rapidly disperses (disintegrates) in a small amount ofaqueous fluid. Some embodiments of the invention include those whereinthe matrix disperses in about 30 sec or less, about 20 sec or less,about 15 sec or less, about 10 sec or less, or about 5 sec or less whenplaced in a small amount of aqueous fluid. In some embodiments, thedisintegration time is determined according to USP <701>.

A method of treating a disease or disorder that is therapeuticallyresponsive to OXC is provided. The method comprises daily administrationof one, two or three dosage forms of the invention to a subject in needthereof over a treatment period lasting days, weeks or months therebyreducing or eliminating one or more symptoms of the disease or disorder.In some embodiments, a 3DP dosage form comprising a dose of about 150 toabout 1200 mg, or about 150 to about 600 mg is administered twice dailyfor a treatment period.

A method of preparing an orodispersible dosage form is also provided.The method comprises forming a non-compressed porous matrix as describedherein by forming incremental layers of powders and depositing printingfluid on each incremental layer to bind disintegrant, binder,surfactant, glidant, sweetener and drug-containing particles of OXC intoa rapidly orodispersible non-compressed porous matrix.

The invention includes all combinations of the aspects, embodiments andsub-embodiments disclosed herein.

BRIEF DESCRIPTION OF THE FIGURES

The following figures form part of the present description and describeexemplary embodiments of the claimed invention. The skilled artisanwill, in light of these figures and the description herein, be able topractice the invention without undue experimentation.

FIG. 1 depicts a sectional front elevation of an orodispersible dosageform made from a three-dimensionally printed matrix comprisingsequentially-formed incremental layers of bound bulk material.

FIG. 2 depicts a sectional front elevation of an alternate embodiment ofan orodispersible dosage form made from a three-dimensionally printedmatrix.

FIGS. 3A-3E depict various different printing patterns that can be usedto apply printing fluid to incremental layers of powder.

FIG. 4A depicts a sectional front elevation of an alternate embodimentof an orodispersible dosage form made from a three-dimensionally printedmatrix.

FIG. 4B depicts a perspective view of the dosage form of FIG. 4A.

DETAILED DESCRIPTION OF THE INVENTION

As used herein and unless otherwise specified, the term oxcarbazepine(OXC) refers to the drug in underivatized(10,11-Dihydro-10-oxo-5H-dibenz[b,f]azepine-5-carboxamide) orderivatized form. Oxcarbazepine is available from Jubilant Life Sciences(Nanjangug, Mysore, Karnataka, India), CTX Life Sciences Pvt. Ltd.(Sachin, Surat, Gujarat, India), Trifarma S.p.A (Milano, Italy) andFabrica Italiana Sintetici S.p.A (Montecchio Maggiore-Vicenza, Italy).OXC can be present in crystalline or amorphous form. Polymorphs ofoxcarbazepine have been recognized recently (e.g., in J. Pharm Sci 99(2) 2010: 794-803) and are considered to be within the scope of the termoxcarbazepine.

As used herein, “native particles” refers to particles of a compoundwithout any other added components, i.e. native particles of OXC areparticles containing OXC, wherein the particles do not contain any addedexcipient(s). “Drug-containing particles” refers to preformed particlescomprising “native particles of OXC” and one or more excipients. Thedrug-containing particles are necessarily larger in size than the nativeparticles. The drug containing particles can be granules, beads,pellets, or other engineered particles or agglomerates that otherwiseincorporate the smaller, primary drug particles themselves and canwithstand conventional powder handling for flow and transfer.

As used herein and unless otherwise specified, “particle size” and“actual particle size” refer to the particle size of a compound withoutany other added component(s), i.e. the particle size of the nativeparticles of OXC, or refers to the particle size of the drug-containingparticles.

The present invention provides a rapidly orodispersible dosage formcomprising drug-containing particles comprising OXC and one or morepharmaceutical excipients. The dosage form comprises a non-compressedmatrix of particles bound by binder. The matrix comprises thedrug-containing particles, disintegrant, binder, surfactant, glidant,sweetener and glycerin. The matrix is porous and disperses within lessthan 20 sec when placed in a small amount of water.

The impact of particle size of OXC upon characteristics of a 3DPorodispersible dosage form was evaluated by directly blending OXC withother excipients to form the powder material used for printing. It wasdetermined that lots with very small particle size, e.g. mean particlesize>10 microns, produced dosage forms with unacceptably rough surfacesand poor (unacceptably low) hardness. Lots with large mean particlesize, e.g. 40-50 microns, produced better surface texture and hardness;however, those particles are substantially larger than desired for oraladministration.

Inventive drug-containing particles of OXC were prepared using smallparticle size OXC, disintegrant, binder, and glidant. The inventiveparticles were prepared by wet granulation according to Example 1. Wetgranulation can be conducted in a low shear mixer, e.g. planetary mixer,or high shear mixer, e.g. GMX mixer. Comparator drug-containingparticles were prepared by dry granulation with roller compaction.

The ratio of effective particle size to native drug particle size willvary according to the respective mean, median, average or D50 particlesize distributions: the smaller the native particle size and the largerthe effective particle size, then the larger the ratio, and vice versa.For example, if the average native particle size is such that 90%-100%of the drug is <10 microns, then the ratio of effective particle size tonative particle size might be in the range of 10:1 to 200:1. Likewise,if the average native particle size is such that NMT 20% of the drug is<32 microns, 40-70% of the drug is <63 microns, 70-95% of the drug is<125 microns, and 100% of the drug is <250 microns, then the ratio ofeffective particle size to native particle size might be in the rangeof >1:1 to about 10:1. Accordingly, the ratio can be in the rangeof >1:1 to about 200:1, or 2:1 to 100:1, or 3:1 to 50:1. Use of morethan one grade of native drug is contemplated, which may comprise one ormore native particle size distributions. In some embodiments having morethan one grade of native drug, more than one ratio of effective particlesize to native drug particle size may be used to describe the relativeparticle sizes. In some embodiments, there is a first ratio of effectiveparticle size to native particle size of >1:1 to 5:1 with respect to afirst native API, and a second ratio of effective particle size tonative particle size of 20:1 to 50:1 with respect to a second nativeAPI.

Then, three-dimensionally printed (3DP) dosage forms comprising thevarious different drug-containing particles of OXC were preparedaccording to Example 3. The resulting 3DP dosage forms were evaluatedfor hardness, dispersion time and friability to determine which of thedrug-containing particles provided suitable 3DP orodispersible dosageforms with very rapid dispersion times, adequate hardness and minimalfriability. It was determined that only the drug-containing particlesmade by wet granulation, preferably high shear wet granulation, provided3DP dosage forms meeting these stringent performance criteria. None ofthe comparator formulations made by dry granulation provided 3DP dosageforms meeting these stringent performance criteria. This finding isquite unexpected, since the compositions of the comparatordrug-containing particles were the same as those of the inventivedrug-containing particles

The weight ratio of OXC to other excipients in the drug-containingparticles can be varied; however, doing so will have an impact uponhardness, dispersion time, friability, dosage form size and dose of drugin the dosage form. If the excipient content in the drug-containingparticles is too low, performance of the dosage form is sacrificed. Ifexcipient content in the drug-containing particles is too high, thedosage form size has to be increased substantially in order to include asuitable dose of OXC therein, thereby making it extremely difficult toprepare reasonably sized dosage forms containing high amounts of OXC.

Drug-containing particles, especially granules prepared by wetgranulation, can be used to prepare rapidly dispersible 3DP matricescomprising OXC having a hardness in the range of 1-3 kP and a dispersiontime in water of 15 sec or less, or 10 sec or less. Suitabledrug-containing particles comprise 65-70% wt OXC, 21.5-23% wtdiluent/disintegrant, e.g. microcrystalline cellulose, 3-5% wtsuperdisintegrant, e.g. croscarmellose, 1-4.5% wt surfactant, e.g.sodium lauryl sulfate, and 2.5-5% binder, e.g. hydroxypropylcellulose.Drug-containing particles produced by high shear wet granulation had aDv0.5 of about 60-100 microns.

It has been determined that inclusion of a surfactant in the printingfluid, bulk powder and drug-containing particles aids in ensuring rapiddispersion of the 3DP dosage form when placed in a minimal amount ofwater. The surfactant serves to enhance wetting of the particles. Thesurfactant need only be present in an amount sufficient to enhancedispersion as compared to another 3DP dosage form excluding thesurfactant. If the surfactant is present in too high of an amount,however, it will negatively impact mouth feel, performance and/orphysical properties of the dosage form. The surfactant can be includedin the drug-containing granule, bulk powder and/or printing fluid. Insome embodiments, the total amount of surfactant present in thedrug-containing particles ranges from about 0-5%, >0-5%, 1-4.2%, 2-3%wt. based upon the weight to the drug-containing particles. In someembodiments, the amount of surfactant present in the bulk powder,excluding the drug-containing particles, ranges from about 0-5%, >0-5%,1-4.2%, 2-3% wt. based upon the weight to the bulk powder.

The rapidly dispersible dosage form can disperse (disintegrate) in about30 seconds or less, about 20 seconds or less, about 15 seconds or less,about 10 seconds or less, about 5 sec or less, about 4 sec or less, orabout 3.5 sec or less when placed in a small volume of aqueous fluid,such as a saliva, gastric fluid and/or a sip of water. In someembodiments, the dispersion (disintegration) time is measured in a smallvolume of 20 ml or less, 15 ml or less, 10 ml or less, 5 ml or less, 3ml or less and at least 1 ml of an aqueous fluid. In some embodiments,the disintegration time is determined according to USP <701>.

The small volume of aqueous fluid can be a sip such as a volume 50 ml orless, 40 ml or less, 30 ml or less, 20 ml or less, 10 ml or less, 5 mlor less, 2.5 ml or less or 1 ml or less. The small volume can be atleast 0.1 ml, at least 0.25 ml, at least 0.5 ml, at least 0.75 ml, atleast 1 ml, at least 1.5 ml or at least 2 ml. All possible combinationsof these volumes are contemplated. Suitable ranges for the small volumeinclude 0.1 to 50 ml, 0.1 to 40 ml, 0.1 to 30 ml, 0.1 to 20 ml, 0.1 to10 ml, 0.2 to 10 ml, 0.3 to 10 ml, 0.5 to 10 ml, 1 to 10 ml, 5 to 10 ml,1 to 7.5 ml, 1 to 5 ml, 0.5 to 3 ml, or other such ranges. Preferably,the sip is about 15 ml (one tablespoon) of water. Preferably a sip isabout 2 to about 30 ml, about 10 to about 15 ml (1 tablespoon) or about13 ml of water (fluid).

In some embodiments, the dosage form comprises not more than 10% wt.,not more than 7.5% wt., not more than 5% wt., not more than 4% wt., notmore than 3% wt., not more than 2.5% wt., not more than 2% wt. or notmore than 1.5% wt. moisture as determined by loss on drying (LOD) at120° C. In some embodiments, the dosage form comprises at least 0.1%wt., at least 0.2% wt., at least 0.5% wt., at least 0.75% wt., at least1% wt., at least 1.5% wt., at least 2% wt., at least 2.5% wt., at least3% wt., at least 4% wt., or at least 5% wt. moisture as determined byloss on drying at 120° C. In some embodiments, the dosage form comprises0.1 to 10% wt, 0.2 to 7.5% wt, 0.25 to 5% wt, 0.5 to 4% wt or 0.75-2% wtmoisture. All combinations of these various limits are within the scopeof the invention.

In some embodiments, the overall hardness (as determined by a tabletbreaking force assay according to USP <127>) of the matrix ranges fromabout 0.5 kiloponds (kp) to about 5 kp or from about 1 kp to about 3 kP.In some embodiments, the overall hardness is at least 1.0 kp, at least1.5 kp or at least 2 kp. In some embodiments, the overall hardness is nomore than 5 kp, no more than 4 kp or no more than 3 kp.

The term friability is the tendency of the matrix to lose material fromits outer edges and surfaces upon mechanical insult. Friability isreduced by increasing the hardness. In some embodiments, the dosage formpossesses a friability of less than about 25%, preferably less thanabout 10% as determined according to USP <1216> and as further describedbelow.

In some embodiments, the porosity of the matrix ranges from about 10% toabout 90% or from about 30% to about 70% of the dosage form volume.

In some embodiments, the bulk density of the matrix (as determined bymeasurement of weight and dimensions and calculation) ranges from 150(mg/mL) to about 1300 (mg/mL), 200-1000 (mg/ml), or from about 300(mg/mL) to about 700 (mg/mL).

The rapidly dispersible dosage form of the invention is made by athree-dimensional printing (3DP) process. Suitable equipment assembliesfor three-dimensional printing of articles are commercially available orare already in use: Massachusetts Institute of TechnologyThree-Dimensional Printing Laboratory (Cambridge, Mass.), ZCorporation's 3DP and HD3DP™ systems (Burlington, Mass.), The Ex OneCompany, L.L.C. (Irwin, Pa.), Soligen (Northridge, Calif.), SpecificSurface Corporation (Franklin, Mass.), TDK Corporation (Chiba-ken,Japan), Therics L.L.C. (Akron, Ohio, now a part of IntegraLifesciences), Phoenix Analysis & Design Technologies (Tempe, Ariz.),Stratasys, Inc.'s Dimension™ system (Eden Prairie, Minn.), ObjetGeometries (Billerica, Mass. or Rehovot, Israel), Xpress3D (Minneapolis,Minn.), and 3D Systems' Invision™ system (Valencia, Calif.). Othersuitable 3DP systems are disclosed in U.S. No. 20080281019, No.20080277823, No. 20080275181, No. 20080269940, No. 20080269939, No.20080259434, No. 20080241404, No. 20080231645, No. 20080229961, No.20080211132, No. 20080192074, No. 20080180509, No. 20080138515, No.20080124464, No. 20080121172, No. 20080121130, No. 20080118655, No.20080110395, No. 20080105144, No. 20080068416, No. 20080062214, No.20080042321, No. 20070289705, No. 20070259010, No. 20070252871, No.20070195150, No. 20070188549, No. 20070187508, No. 20070182799, No.20070182782, No. 20060268057, No. 20060268044, No. 20060230970, No.20060141145, No. 20060127153, No. 20060111807, No. 20060110443, No.20060099287, No. 20060077241, No. 20060035034, No. 20060030964, No.20050247216, No. 20050204939, No. 20050179721, No. 20050104241, No.20050069784, No. 20050061241, No. 20050059757, No. 20040265413, No.20040262797, No. 20040252174, No. 20040243133, No. 20040225398, No.20040183796, No. 20040145781, No. 20040145628, No. 20040143359, No.20040141043, No. 20040141030, No. 20040141025, No. 20040141024, No.20040118309, No. 20040112523, No. 20040012112, No. 20040005360, No.20040005182, No. 20040004653, No. 20040004303, No. 20040003741, No.20040003738, No. 20030198677, No. 20030143268, No. 20020125592, No.20020114652, No. 20020079601, No. 20020064745, No. 20020033548, No.20020015728, No. 20010028471, and No. 20010017085; U.S. Pat. No.5,490,962, No. 5,204,055, No. 5,121,329, No. 5,127,037, No. 5,252,264,No. 5,340,656, No. 5,387,380, No. 5,490,882, No. 5,518,680, No.5,717,599, No. 5,851,465, No. 5,869,170, No. 5,879,489, No. 5,934,343,No. 5,940,674, No. 6,007,318, No. 6,146,567, No. 6,165,406, No.6,193,923, No. 6,200,508, No. 6,213,168, No. 6,336,480, No. 6,363,606,No. 6,375,874, No. 6,508,971, No. 6,530,958, No. 6,547,994, No.6,596,224, No. 6,772,026, No. 6,850,334, No. 6,905,645, No. 6,945,638,No. 6,989,115, No. 7,220,380, No. 7,291,002 No. 7,365,129, No.7,435,368, No. 7,455,804, No. 7,828,022, No. 8,017,055; PCTInternational Publications No. WO 00/26026, No. WO 98/043762, No. WO95/034468, No. WO 95/011007; and European Patent No. 1,631,440, whichemploys a cylindrical (radial or polar) coordinate-based system due toits construction. The entire disclosure of each of these references ishereby incorporated herein.

The 3DP process described herein requires a powder layering system thatforms a layer of powder and printing system that applies a printingfluid to the layer of powder according to a predetermined pattern,thereby forming an incremental printed layer. The printing fluid servesto form bound particles of powder, i.e. particles that are adhered toone another by one or more pharmaceutical excipients and/or one or moreactive ingredients. Incremental printed layers are formed one on top ofanother to vertically build the dosage form of the invention, therebyforming a dosage form comprising plural incremental printed layers. Theprocess of spreading powder and depositing droplets is repeated untilthe desired number of layers for the dosage form is complete. Theincremental layers adhere to one another due to bleeding of printingfluid from one layer to an adjacent other layer such that one or moreexcipients and/or one or more active ingredients adhere to both adjacentlayers. Following completion of the initial three-dimensional structure,residual printing fluid is removed from or reduced in the dosage form bydrying. The evaporation of solvent during the drying process leaves amatrix having a three-dimensional architecture comprising the particlesof bulk material bound by solidified binder and/or other componentsincluding one or more active ingredients and/or any optionalpharmaceutically acceptable excipients.

The three-dimensional printing process is normally conducted at ambienttemperatures. The process can utilize a variety of printing fluids,including biologically compatible organic and aqueous solvents. Theprocess is additive, whereby microscopic features are incorporated layerby layer, allowing a wide range of possible architectures to beconstructed precisely on a sub-millimeter scale. Using three-dimensionalprinting to control simultaneously both the microscopic features and themacroscopic shape, the unique drug delivery systems of the presentinvention are obtained.

A particularly suitable printing assembly for three-dimensional printingof the instant dosage form is described in U.S. application No.61/696,839, filed Sep. 5, 2012, the disclosure of which is herebyincorporated by reference in its entirety. The assembly includes buildmodules each having an incrementally height adjustable platform disposedwithin a cavity of the build modules, a powder layering system, aprinting system, a printing fluid removal system and a dosage formhandling system.

In general, at least two components are used in the three-dimensionalprinting process used to prepare the matrix of the rapidly dispersingdosage forms. The first component is the powder material to be includedin the incremental powder layers. The second component is the printingfluid (in some cases the fluid may also contain a binder) that isdispensed by a printhead onto the powder layer. In some embodiments, thepowder material is comprised of bulk powder comprising plural excipientsand of drug-containing particles comprising OXC and plural excipients.The excipients in the bulk powder can be the same as or different thanthe excipients in the drug-containing particles. In some embodiments,one or more excipients in the bulk powder is different that one or moreexcipients in the drug-containing particles.

At least one component of the matrix must serve as a “binding agent”that binds particles of bulk powder together in the completedthree-dimensional matrix. The binding agent produces adhesion betweenparticles of the bulk powder and drug-containing particles. It is thisadhesion that enables the dosage form to maintain a fixed shaped(geometry) and maintain its characteristics of hardness and friabilityadequate to permit handling and storage. The strength and extent of thebinding depends on the proportion of the binding agent either in thepowder layer or dissolved in the solvent, and is a function of theamount of fluid deposited. The term adhesion means the bonding orbinding of particles of the bulk material to each other or to particlesof another material present. There are various ways in which a bindingagent can be included in the matrix. The invention contemplates acombination of one or of two or more of these different ways.

In some embodiments of the method of preparation of the matrix, bindingagent is present in the bulk powder, the drug-containing particles, theprinting fluid, or a combination or two or three thereof. A bindingagent in the printing fluid can be the same as or different than abinding agent in the bulk powder and/or drug-containing particles.

The binding agent can be a pharmaceutically acceptable binder. Includinga pharmaceutical “binder” as the binding agent in the printing fluidwill result in a different internal microstructure of the dosage forms,particularly the pore size, than the internal microstructure of anotherwise same dosage form excluding binder in the binding solution.Upon printing, as the solvent evaporates, binder remains as a solidresidue, which occupies void space in between powder particles, e.g.particles of disintegrant or drug. The resulting structure will havehigher density compared to tablets fabricated without binder in theprinting fluid.

The invention provides a process for the preparation of a rapidlydispersing solid dosage form comprising a three-dimensionally printedsolid porous matrix comprising a bulk powder, binder and drug-containingparticles of OXC, the process comprising: (a) providing a powderedmixture of one or more disintegrants, one or more binders, one or moresweeteners, one or more humectants, one or more glidants anddrug-containing particles (comprising OXC and one or more excipients),together with any optional pharmaceutically acceptable excipients; (b)forming an incremental layer of the powdered mixture; (c) applying tothe incremental layer droplets of printing fluid according to apredetermined pattern to form a printed incremental layer; (d) repeating(b) and (c) a predetermined number of times, thereby providing athree-dimensionally printed moist matrix; and (e) removing or reducingthe amount of printing fluid in the moist matrix, thereby providingthree-dimensionally printed solid porous matrix having a composition,moisture content, porosity, overall bulk density, hardness, matrixdispersion time, in vitro drug dissolution time, in vitro dispersionbehavior, in vivo pharmacokinetic behavior, structure, incremental layerthickness, drug particle size, drug-containing particle particle size,disintegrant particle size, drug content, and/or friability within theranges specified herein.

The dosage form of the present invention may be further shaped asdesired to facilitate placement thereof in the buccal cavity of asubject. One such embodiment may be a wafer-like shape, donut, ring,tube, cube, spheroid, ellipsoid or rectangular box.

FIG. 1 depicts a sectional front elevation of an orodispersible dosageform (1) made from a three-dimensionally printed matrix comprisingsequentially-formed incremental layers of bound bulk material (2-3). Theexterior surfaces (3) envelope a middle portion (2). The exteriorsurfaces have a greater hardness than the interior portion. This dosageform is made by three-dimensionally printed plural incremental layers.The bottom incremental layer, which defines the lower surface, and theupper incremental layer, which defines the upper surface, and thecircumferential surfaces (left and right of the middle portion) areharder than the interior portion. The increased hardness is achieved byusing a higher saturation level, higher content of binder or asotherwise described herein. The increased hardness at the periphery ofthe incremental layers of the middle portion is achieved by increasingthe saturation level and/or content of binder at the periphery, but notthe center (non-peripheral portion) of the respective incrementallayers.

FIG. 2 depicts a sectional front elevation of an alternate embodiment ofan orodispersible dosage form (5) made from a three-dimensionallyprinted matrix. The bottom incremental layer, which defines the lowersurface (8), and the upper incremental layer, which defines the uppersurface (7) are harder than the interior portion (6) comprising pluralincremental layers. The dosage forms (1) and (5) differ primarily in theprocess used to print the middle incremental layers, the layers of (6)not having a periphery with increased hardness.

FIGS. 3A-3E depict the top plan view of three different print patternsthat can be used to prepare the printed incremental layers of a 3DPorodispersible matrix of the invention. Even though each print patternis depicted as being circular, substantially any geometry can be used,e.g. circle, oval, square, rectangle, oblong circle, etc. FIG. 3Adepicts a first solid print pattern wherein substantially the same full,heavy or higher saturation level is used throughout the entire printarea. FIG. 3B depicts a second solid print pattern wherein substantiallythe same medium, low, light or lower saturation level is used throughoutthe entire print area. This second solid pattern is referred to as agrayscale pattern since it has a reduced saturation level. FIG. 3Cdepicts an annular (hollow) print pattern wherein printing fluid isapplied to the periphery of the print area but not toward the center ofthe print area. FIG. 3D depicts a combination annular and grayscaleprint pattern wherein printing fluid is applied to the periphery of theprint area at a higher saturation level and toward the center of theprint area at a grayscale (reduced) saturation level. FIG. 3E depicts anindicum print pattern wherein substantially the same saturation level isused throughout the entire print area except in the indicum region(s)wherein no printing fluid is applied thereby forming a debossed indicumin the surface of the final dosage form.

In some embodiments, the dosage form comprises (consists essentially ofor consists of) the following types of printed incremental layers: a)plural layers of first solid print pattern, and plural layers ofcombination annular and grayscale print pattern; b) plural layers offirst solid print pattern, plural layers of annular print pattern, andplural layers of combination annular and grayscale print pattern; c)plural layers of first solid print pattern, plural layers of annularprint pattern, plural layers of combination annular and grayscale printpattern, and plural layers of indicum print pattern; d) plural layers offirst solid print pattern, plural layers of annular print pattern,plural layers of combination annular and grayscale print pattern, plurallayers of first solid print pattern, and plural layers of indicum printpattern; e) plural layers of first solid print pattern, plural layers ofgrayscale print pattern, and plural layers of first solid print pattern;f) plural layers of grayscale print pattern; g) plural layers ofcombination annular and grayscale print pattern; h) plural layers offirst solid print pattern; i) plural layers of first solid print patternand plural layers of annular print pattern; or j) plural layers of firstsolid print pattern, plural layers of combination annular and grayscaleprint pattern, and plural layers of indicum print pattern.

In some embodiments, the dosage form comprises (consists essentially ofor consists of) the following types of incremental layers grouped intorespective sections of the dosage form: a) a first end comprising plurallayers of first solid print pattern; a middle portion comprising plurallayers of annular print pattern and plural layers of combination annularand grayscale print pattern; and a second end comprising plural layersof indicum print pattern; b) a first end comprising plural layers offirst solid print pattern; a middle portion comprising plural layers ofcombination annular and grayscale print pattern; and a second endcomprising plural layers of first solid print pattern and/or plurallayers of indicum print pattern; c) a first end comprising plural layersof first solid print pattern; a middle portion comprising plural layersof annular print pattern, plural layers of combination annular andgrayscale print pattern; and a second end comprising plural layers offirst solid print pattern and/or plural layers of indicum print pattern;or d) a first end comprising plural layers of first solid print pattern;a middle portion comprising alternating groups of layers, wherein onegroup comprises plural layers of annular print pattern, and anothergroup comprises plural layers of combination annular and grayscale printpattern; and a second end comprising plural layers of first solid printpattern and/or plural layers of indicum print pattern.

The dosage form can also be shaped as a donut, ring or tube. FIG. 4Adepicts an exemplary dosage form wherein the core of the dosage formabout the vertical axis of the cylindrical shape has been left out orremoved during manufacture of the dosage form. The diameter of the boreor hole can be in the range of 3-10 mm. In some embodiments, the hole iscreated via an unprinted zone within the dosage form and reaching atleast one exterior surface such that unbound powder empties out. FIG. 4Bdepicts a perspective view of the dosage form of FIG. 4A.

The physical properties of the dosage form can be controlled by varyingincremental powder layer thickness, powder composition, printing fluidcomposition, printing fluid saturation level (print density) on a layer,and identity and amount of the excipients included within the dosageform, e.g. identity and amount of disintegrant, binder, sweetener,surfactant. These variables exhibit different levels of effect upondosage form hardness, bulk density, disintegration time, dissolutiontime, bioavailability, moisture content, taste, and friability. It wasdetermined that the result effective variables include, at least, theamount of drug, amount of disintegrant, amount of binder, layerthickness, identity of some components, and composition of thedrug-containing particles.

Three-dimensional printing can have spatial descriptors in each of threedifferent, typically orthogonal directions. In three-dimensionalprinting, fluid may be deposited in drops or in fluid units resemblingdrops. Drops may be deposited in a succession that forms a linecorresponding to the motion of the printhead. The spacing between thosedrops is the drop-to-drop spacing. After completion of one line, anotherline may be deposited adjacent to the earlier-deposited line andseparated from the earlier-deposited line by a distance that is aline-to-line spacing. After completion of printing on a layer of powder,another powder layer may be deposited, with each powder layer having alayer thickness. The powder layer thickness is the third descriptor.

In some instances, the spacing of droplets may be described in terms ofthe resolution of the printing system, often expressed as dots per inch(dpi), which is the reciprocal of droplet spacing. For example,resolutions of 300 and 600 dpi correspond to droplet spacing's of about84.7 microns and about 42.3 microns, respectively. The drop-to-dropspacing (within a line), or the line spacing (spacing of droplets fromone line to the next), or any other spacing of droplets may be describedin terms of resolution expressed in dpi. In some instances,layer-by-layer instructions for making the dosage forms may consist of aseries of pixelated images characterized by a resolution indots-per-inch in each of two orthogonal linear directions. In someinstances, these pixelated images are 1-bit monochrome images,alternately referred to as binary or bi-level images in which each pixelcontains one bit of information (0 or 1) that may be represented aseither black or white onscreen.

In some instances, the relative amount of binding in localized regionsof the dosage form is achieved by “grayscaling” (i.e., use of agrayscale print pattern) in the dosage form design. In the case of 1-bitmonochrome images used for machine instructions, grayscaling is achievedby changing the number of “black” pixels relative to “white” pixels in achosen region of a dosage form, or in a chosen layer of a dosage form,or throughout a dosage form. Any other regions that may be “solid” byusing all black pixels. In some embodiments, the dosage form designincludes a “solid” exterior and a “grayscaled” interior. In someembodiments, grayscaling may be achieved with equally spaced blackpixels amongst white pixels to reach an overall ratio of black to whitepixels in the grayscaled region. In other embodiments, grayscaling maybe achieved with randomly placed black pixels amongst white pixels toachieve an overall ratio of black to white pixels in the grayscaledregion. In still other embodiments, grayscaling may be achieved with achosen pattern (e.g., parallel lines, hashed pattern, dot pattern) ofblack pixels amongst white pixels to achieve an overall ratio of blackto white pixels in the grayscaled region.

In three-dimensional printing, a voxel or unit volume may be defined byone drop-to-drop spacing in the fast axis direction of motion, by oneline-to-line spacing in the slow axis direction of motion, and by onelayer thickness in the vertical direction. Some of this unit volume isoccupied by powder particles, and the remainder of the unit volume isempty space that collectively has a volume that is the void volume.

The saturation level (print density) describes how much of the voidspace in this unit volume is occupied by liquid which is dispensed in adrop or fluid unit which is dedicated to that particular voxel. Thesaturation level is the ratio of the dispensed fluid volume to thevolume of empty space in the voxel. In general, in three-dimensionalprinting, saturation levels may be chosen to be slightly less than, orsomewhere approximately equal to, 1.0, also expressed as 100%.Excessively low saturation levels tend to result in poor structuralintegrity. Excessively high saturations levels tend to result inexcessive bleeding of liquid beyond where the liquid was deposited. Inthe present dosage form, the saturation level during the step ofapplying printing fluid to a powder layer ranges from about 85% to about120%, about 10% to about 110%, about 15% to about 80%, about 20% toabout 50% or about 15% to about 35% in aggregate across the dosage form,or otherwise in selected regions of the dosage form.

Suitable printing devices include those having a continuous jetprinthead or those having a drop-on-demand printhead. A continuous jetprinthead provides a continuous jet (spray) of droplets while depositingprinting fluid onto a powder layer. A drop-on-demand printhead onlydeposits droplets of printing fluid onto the powder layer if it receivesan instruction (demand, operational command) to do so. A printhead scans(applies fluid to) the surface of powder layer from left to right at apredetermined rate, e.g. a scan rate, to form a line of droplets. A highscan rate will result in a lower saturation level, and a low scan ratewith result in a higher saturation level when comparing printing fluiddeposition at a constant volume per unit time. When considering thesituation where binder is present in the binding solution, an increasein the print speed from 1.0 m/s to 2.0 m/s reduces the total volume ofbinder solution deposited in the tablets by half. As the print speedincreases, the bulk density (theoretical, calculated from the weight anddimensions of the tablet) decreases. A simultaneous decrease in thedimensions and weight of the tablets is also seen. This decrease isattributed to the fact that a decrease in the total volume of binderdroplets deposited onto the powder results in a decrease in the extentof binder solution spreading in the powder. As expected, increasing theprint speed also decreases the flash time and the hardness and increasesthe friability of the tablets. This result is obtained because theproportion of binder decreases in the tablets as the print speedincreases. An increase in the print speed also increases the void volumeinside the tablets, as illustrated by an increase in the percent volumeof the tablets penetrated by mercury at 30 psi (% intrusion).

When using a continuous jet printhead, the printhead scans at a rate ofabout 0.5 to 3.0 msec, and most preferably at about 1.75 msec. Whenusing a drop-on-demand jet printhead, the printhead scans at a rate of0.1 to 1 msec, most preferably at about 0.5 m/sec.

The volume of individual droplets can be varied as desired. Increasingthe volume of the droplet increases the saturation level and decreasingthe volume of a droplet decreases the saturation level when comparingprinting fluid deposition at a constant scan rate. When using acontinuous jet printhead, the size of the fluid droplets delivered bythe printhead preferably ranges from about 15 μm to about 150 μm indiameter. When using a drop-on-demand printhead, the size of the fluiddroplets delivered by the printhead preferably ranges from about 50 μmto about 500 μm in diameter.

The flow rate of the fluid delivered by the printhead can be varied asdesired. Increasing the flow rate will increases the saturation leveland decreasing the flow rate decreases the saturation level whencomparing printing fluid deposition at a constant scan rate. Asdiscussed herein, the printhead deposits droplets of printing fluid toform parallel lines thereof in the powder layer. When using a continuousjet printhead, the line spacing ranges from about 20 to about 1000 μm,about 50 to about 500 μm, or and preferably about 100 to 200 μm. Whenusing a drop-on-demand jet printhead, the line spacing ranges from about100 to about 1500 μm, about 250 to about 1000 μm, or preferably areabout 500 to 750 μm.

The powder layering system and the height adjustable platform cooperateto form thin incremental layers of powder in the build modules. Thetotal thickness (height) of the dosage form will be a function of thenumber and thickness of the incremental layers. The number of printedincremental layers typically ranges from 5 to 50. A matrix willtypically comprise (consist essentially of or consist of) 20 to 50, 20to 40, 30 to 40 or 30 to 35 printed incremental layers. The “end”section of a dosage form will typically comprise 1 to 10, 1 to 7, 2 to7, or 4 to 6 printed incremental layers. An end section with an indicumwill typically comprise 2 to 10, 2 to 7, or 4 to 7 printed incrementallayers. The balance of the printed incremental layers will comprise themiddle portion, with respect to the vertical height, of the dosage form.The middle portion will typically comprise 5 to 40, 10 to 30, 10 to 20,or 20 to 30 printed incremental layers.

The incremental layers are of a predetermined height (verticalthickness), which typically varies from 0.005 to 0.015 inches, 0.008 to0.012 inches, 0.009 to 0.011 inches, 100-300 μm, 100-500 μm, about 200μm, about 250 μm inches. As thicker incremental layers are used, anincreasing amount of printing fluid must be deposited on that layer toensure adequate binding both within the plane of the layer andlayer-to-layer. Conversely, for a thinner incremental layer a lesseramount of printing fluid must be deposited to obtain the same extent ofbinding. For a given amount of printing fluid deposited per layer, usinga larger layer thickness will reduce (worsen) dosage form handleabilityand reduce (improve) dispersion time. If too thick of a layer is usedfor a given amount of fluid, laminar defects may form that cause thedosage form to easily fracture along the plane of the layers(delamination), or the dosage form itself may not have adequate strengthto handle at all. In some embodiments, the thickness of the incrementallayers ranges from 100-400 microns, 150-300 microns, or 200-250 microns.In one preferred embodiment, the layer thickness is 200 microns. Inanother preferred embodiment, the layer thickness is 250 microns.

Dosage forms produced by the 3DP process described herein vary in sizeaccording to the content of OXC and the respective drug-containingparticles. In order to minimize dosage form size, the content ofdrug-containing particles should be maximized and the content of OXC inthe drug-containing particles should be maximized; however, as describedherein, the resulting dosage form must possess sufficient hardness and avery rapid dispersion time. When the content of OXC in thedrug-containing particles is in the range of 65-70% wt, and the contentof drug-containing particles in the matrix is about 60%, a matrix havinga 150 mg dose of OXC can weigh about 380-390 mg, a matrix having a 300mg dose of OXC can weigh about 770-780 mg, and a matrix having a 600 mgdose can weigh about 1540-1560 mg. Accordingly, if the matrix comprisesa higher percentage of drug-containing particles or if drug-containingparticles having a higher percentage of OXC are employed, the dosageform weight can be decreased correspondingly and vice versa.

One or more pharmaceutically acceptable excipients can be included inbulk powder material and/or the printing fluid. Each excipient may beindependently selected upon each occurrence from a water soluble,aqueous fluid soluble, partially water soluble, partially aqueous fluidsoluble, water insoluble or aqueous fluid insoluble excipient as neededto provide the required particle-to-particle binding in a printedmatrix.

Most pharmaceutically acceptable excipients, both small molecules andpolymers, can be employed, which allow a pharmaceutically activeingredient to be loosely encased in a porous structure (a matrix ofbound particles) that is subject to rapid dispersion in the presence ofan appropriate aqueous fluid, e.g., saliva. Some of these excipients,suitable for use in the three-dimensional printing process of theinvention, are listed in the Handbook of Pharmaceutical Excipients (Eds.A. Wade and P. J. Weller, Second edition, American PharmaceuticalAssociation, The Pharmaceutical Press, London, 1994).

Suitable types of excipients for the dosage form include binder,disintegrant, dispersant, sweetener, glidant, flavorant, surfactant,humectant, preservative and diluent. Although conventionalpharmaceutical excipients may be used, they may not always function inprecisely the same manner as with traditional pharmaceutical processing

One or more binders can be included in the printed matrix. The bindermay be included in either the bulk powder, drug-containing particlesand/or in the printing fluid dispensed through the printhead. The binderis independently selected upon each occurrence. Adhesion of theparticles to and/or by the binder occurs either when the binder iscontacted by the printing fluid from the printhead or when it is present(i.e., soluble) in the printing fluid. The binder is preferably watersoluble, aqueous fluid soluble, partially water soluble or partiallyaqueous fluid soluble. In some embodiments, the printing fluid comprises0-10% wt of binder. In some embodiments, the bulk powder comprises >0 to50% wt, 10% to 45%, 20% to 45%, 25-40%, 25-35% wt of binder. In someembodiments, the drug-containing particles comprise >0 to 10%, 2 to 10%,2 to 7%, or 2 to 5% wt of binder. In some embodiments, the printedmatrix comprises >0 to 50% wt, 10% to 45%, 20% to 45%, 25-40% wt ofbinder. In some embodiments, binder is absent from the printing fluid orabsent from the bulk material.

Suitable binders include water-soluble synthetic polymer,carboxymethylcellulose, hydroxypropylcellulose, polyvinlypyrrolidone,hydroxypropyl-methylcellulose, sorbitol, mannitiol, xylitol, lactitol,erythritol, pregelatinized starch, modified starch, arabinogalactan.Preferred binders include polyvinylpyrrolidone (povidone), mannitol,hydroxypropylcellulose, or a combination thereof.

The following materials are considered binders, even though they exhibitlow strength binding: spray dried lactose, fructose, sucrose, dextrose,sorbitol, mannitol, xylitol,

One or more disintegrants can be included in the printed matrix. Thedisintegrant can be present in the bulk powder and/or drug-containingparticles. The disintegrant is independently selected upon eachoccurrence. In some embodiments, the bulk powder comprises 3-20% wt,3-15% wt, 4-12% wt or 10-16% wt of disintegrant. In some embodiments,the drug-containing particles comprise 15-35% wt, 20-30% or 25-30%% wtof disintegrant.

Suitable disintegrants include microcrystalline cellulose (MCC),croscarmellose (cross-linked carboxymethylcellulose), powdered celluloseor a combination thereof. Preferred disintegrants includemicrocrystalline cellulose, e.g. AVICEL® PH 101, a combination of twogrades of microcrystalline cellulose, and croscarmellose. Suitablegrades of AVICEL® are summarized in the table below. The dosage form cancomprise one or a combination of the specified grades. All suchembodiments containing single grades or a combination of grades arecontemplated.

Nominal Particle Moisture, LooseBulk Product Grades Size, μm % Density,g/cc Avicel DG 45 NMT 5.0 0.25-0.40 Avicel PH-101 50 3.0 to 5.00.26-0.31 Avicel PH-102 100 3.0 to 5.0 0.28-0.33 Avicel HFE*-102 100 NMT5.0 0.28-0.33 Avicel PH-102 SCG** 150 3.0 to 5.0 0.28-0.34 Avicel PH-10520 NMT 5.0 0.20-0.30 Avicel PH-102 SCG 150 3.0 to 5.0 0.28-0.34 AvicelPH-200 180 2.0 to 5.0 0.29-0.36 Avicel PH-301 50 3.0 to 5.0 0.34-0.45Avicel PH-302 100 3.0 to 5.0 0.35-0.46 Avicel PH-103 50 NMT 3  0.26-0.31 Avicel PH-113 50 NMT 2   0.27-0.34 Avicel PH-112 100 NMT 1.50.28-0.34 Avicel PH-200 LM 180 NMT 1.5 0.30-0.38 Avicel CE-15 75 NMT 8  N/A NMT means “not more than”.

The binder and disintegrant are key ingredients for controlling thehardness, friability and dispersion time of the matrix. The greater theamount of binder, the higher the hardness, the lower the friability andthe slower the dispersion time. On the other hand, increasing the amountof disintegrant provides lower hardness, increased friability and afaster dispersion time. Accordingly, the matrix of the inventioncomprises a balanced amount of binder and disintegrant.

One or more sweeteners can be included in the printed matrix. Thesweetener can be present in the bulk powder, drug-containing particlesand/or the printing fluid. Better taste-masking is observed when atleast one sweetener is present in at least the printing fluid. Thesweetener is independently selected upon each occurrence. The printingfluid, drug-containing particles and/or the bulk powder can have atleast one sweetener in common In some embodiments, the bulk powdercomprises >0 to 5% wt, or >0 to 2% wt, or >0 to 1.5% wt of sweetener. Insome embodiments, the printing fluid comprises >0 to 5% wt, >0 to 4%wt, >0 to 3% wt, >0 to 2% wt., 0.1 to 5% wt, 0.1 to 4% wt, 0.1 to 3% wt,0.1 to 2% wt, 0.5 to 3% wt, or 1 to 3% wt sweetener. In someembodiments, the drug-containing particles comprise 0-5% wt ofsweetener.

Suitable sweeteners are selected from the group consisting ofglycyrrhizinic acid derivative, e.g. magnasweet (monoammoniumglycyrrhizinate), sucralose and a combination thereof. The preferredsweetener in the printing fluid is sucralose. Sweetener is present in atleast the printing fluid but may also be present in the bulk powder.

One or more flavorants can be included in the matrix. The flavorant canbe present in the bulk powder, drug-containing particles, and/or theprinting fluid. The flavorant is preferably water soluble, aqueous fluidsoluble, partially water soluble or partially aqueous fluid soluble. Ifpresent in the bulk powder, the flavorant is preferably present in aform applied to a carrier powder before preparation of the bulk powder.Suitable carrier powders may include starches, modified starches,celluloses, and other powder capable of absorbing, adsorbing, encasing,or encapsulating the flavorant. In some embodiments, the printing fluidcomprises 0-5% % wt, 0.01-1.0% wt or 0.05-0.5% wt of flavorant. In someembodiments, the bulk powder comprises 0.1 to 10% wt, or 1 to 10% wt, 2to 8% wt, 3-7% wt of flavorant-incorporated carrier powder. In someembodiments, the printed matrix comprises 0-10% wt, 0.01-10% wt offlavorant. In some embodiments, the flavorant is absent from theprinting fluid or absent from the bulk material. Suitable flavorantsinclude peppermint, spearmint, mint, vanilla, orange, lemon, citrus,lime, grape, cherry, strawberry, chocolate, coffee or a combinationthereof.

One or more surfactants can be included in the printing fluid,drug-containing particles or bulk powder. In some embodiments, theprinting fluid comprises 0 to about 10%, >0 to about 7%, or about 1 toabout 5% wt of surfactant. In some embodiments, the drug-containingparticles comprise 0 to about 10%, >0 to about 7%, or about 1 to about5% wt of surfactant. In some embodiments, the bulk powder comprises 0 toabout 10%, >0 to about 7%, about 1 to about 5% wt of surfactant.Suitable surfactants include sodium lauryl sulfate, polysorbate(PEG-ylated sorbitan (a derivative of sorbitol) esterified with fattyacid) or a combination thereof. Suitable polysorbates includepolysorbate 20 (Polyoxyethylene (20) sorbitan monolaurate), polysorbate40 (Polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60(Polyoxyethylene (20) sorbitan monostearate), polysorbate 80(Polyoxyethylene (20) sorbitan monooleate), sodium lauryl sulfate,poloxamer (comprising a central (poly(propylene oxide)) flanked by twochains of (poly(ethylene oxide), e.g. LUTROL), low molecular weightpolyethylene glycol (e.g. PEG 400)

Even though the dosage form can be preservative-free, one or morepreservatives may optionally be included in the printing fluid or powderblend. Suitable preservatives include antifungal or antimicrobialpreservatives such as methylparaben and proprylparaben. In someembodiments, the printing fluid comprises 0.001 to 0.2% preservative.

One or more glidants can be included in the bulk powder and/ordrug-containing particles. In some embodiments, the bulk powdercomprises 0-5% or >0-2% wt of glidant. In some embodiments, thedrug-containing particles comprise 0-5% or >0-2% wt of glidant. Suitableglidants include fumed silica (colloidal silicon dioxide).

The matrix may also comprise glycerin (glycerol) introduced thereineither by way of the bulk powder or the printing fluid. Glycerin canexhibit characteristics of a humectant, sweetener, preservative,lubricant, saponifier or solvent. The present inventors have discoveredthat glycerin unexpectedly behaves contrary to other excipients whenincluded in a three-dimensionally printed dosage form. As noted above,increasing the amount of other excipients disclosed generally results inincreased hardness with concomitantly increased disintegration time;however, increasing the amount of glycerin results in increased hardnessbut unexpectedly reduced disintegration time. The ability of glycerin tobehave in this manner is particularly advantageous and has not beenobserved with any other material incorporated into a three-dimensionallyprinted orodispersible dosage form.

In some embodiments, glycerin is included in the printing fluid.Accordingly, the invention provides a printing fluid for use inthree-dimensional printing wherein the printing fluid comprisesglycerin, water, surfactant and at least one organic solvent. Theinvention also provides a three-dimensional printing method comprising:a) depositing a printing fluid comprising glycerin, water and at leastone organic solvent onto at least one layer of powder; and b) reducingthe content of water and solvent in the at least one layer, therebyforming a three-dimensionally printed porous matrix. The invention alsoprovides a three-dimensional printing system comprising: a) alayer-forming system that forms layers of powder; and b) a printingfluid deposition system that deposits printing fluid onto the layers ofpowder, wherein the printing fluid comprises glycerin, water and atleast one organic solvent.

In some embodiments, the printing fluid comprises 0 to about 20% wt, >0to about 15%, >0 to about 10% or >0 to about 5% wt of glycerin. In someembodiments, the matrix comprises 0 to about 2% or >0 to about 1% wt ofglycerin

In some embodiments, the process of the invention employs a printingfluid comprising at least one or combination of pharmaceuticallyacceptable solvent for at least one material in the bulk powder and/orin the printing fluid itself. The printing fluid may comprise: a) asolvent for a material in the bulk powder; b) a solvent for a materialin the printing fluid; or c) a combination thereof.

Embodiments of the process of the invention include those wherein theprinting fluid comprises a solvent for: a) a binder in the bulk powder;b) a binder in the printing fluid; or c) a combination thereof.

The printing fluid can comprise about 75% to about 95%, or about 80% toabout 90% % wt of water.

The printing fluid can comprise 0 to about 20%, >0 to about 20%, >0 toabout 15%, >0 to about 10%, >0 to about 5% wt of at least one organicsolvent. A suitable organic solvent is alcohol. Suitable alcoholsinclude ethanol, methanol, propanol, isopropanol or a combinationthereof. In some embodiments, the alcohol is ethanol or isopropanol.

It should be understood that compounds used in the art of pharmaceuticsgenerally serve a variety of functions or purposes. Thus, if a compoundnamed herein is mentioned only once or is used to define more than oneterm herein, its purpose or function should not be construed as beinglimited solely to that named purpose(s) or function(s).

The phrase “pharmaceutically acceptable” is employed herein to refer tothose compounds, materials, compositions, and/or dosage forms which are,within the scope of sound medical judgment, suitable for use in contactwith tissues of human beings and animals and without excessive toxicity,irritation, allergic response, or any other problem or complication,commensurate with a reasonable benefit/risk ratio.

As used herein a “derivative” is: a) a chemical substance that isrelated structurally to a first chemical substance and theoreticallyderivable from it; b) a compound that is formed from a similar firstcompound or a compound that can be imagined to arise from another firstcompound, if one atom of the first compound is replaced with anotheratom or group of atoms; c) a compound derived or obtained from a parentcompound and containing essential elements of the parent compound; or d)a chemical compound that may be produced from first compound of similarstructure in one or more steps.

One or more of the components of the formulation can be present in itsfree base or pharmaceutically or analytically acceptable salt form. Asused herein, “pharmaceutically or analytically acceptable salt” refersto a compound that has been modified by reacting it with an acid asneeded to form an ionically bound pair. Examples of acceptable saltsinclude conventional non-toxic salts formed, for example, from non-toxicinorganic or organic acids. Suitable non-toxic salts include thosederived from inorganic acids such as hydrochloric, hydrobromic,sulfuric, sulfonic, sulfamic, phosphoric, nitric and others known tothose of ordinary skill in the art. The salts prepared from organicacids such as amino acids, acetic, propionic, succinic, glycolic,stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic,hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic,2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethanedisulfonic, oxalic, isethionic, and others known to those of ordinaryskill in the art. Lists of other suitable salts are found in Remington'sPharmaceutical Sciences, 17^(th). ed., Mack Publishing Company, Easton,Pa., 1985, p. 1418, the relevant disclosure of which is herebyincorporated by reference.

The invention also provides a method of administering oxcarbazepine to asubject in need thereof. The method comprises: (a) providing a rapidlydispersing, non-compressed matrix dosage form as described herein, and(b) inserting the dosage form into a moisture-containing body cavity,such as the mouth, of a subject in need thereof, the moisture beingcapable of dissolving the binder and dispersing the dosage form within atime period ranging from about one to about twenty seconds, therebydispersing the dosage form in the body cavity. In some embodiments, themethod further comprises the step of administering the dosage form tothe subject, optionally with a sip (small volume) of fluid after thedosage form is placed in the mouth.

The invention also provides a method of treating a disease, disorder orcondition that is therapeutically responsive to oxcarbazepine, themethod comprising: a) administering to a subject in need thereof athree-dimensionally printed orodispersible matrix as described herein oras made by the process described herein. The matrix comprisesoxcarbazepine (in drug-containing particles), a bulk powder, and binder,and the matrix is dispersible in a small volume of fluid. The dosage andadministration regimens detailed in the package inserts for FDA approvedproducts containing oxcarbazepine, e.g. TRILEPTAL®, can be followed foradministering the instant dosage form.

In view of the above description and the examples below, one of ordinaryskill in the art will be able to practice the invention as claimedwithout undue experimentation. The foregoing will be better understoodwith reference to the following examples that detail certain proceduresfor the preparation of embodiments of the present invention. Allreferences made to these examples are for the purposes of illustration.The following examples should not be considered exhaustive, but merelyillustrative of only a few of the many embodiments contemplated by thepresent invention.

EXAMPLE 1 Preparation of Drug-Containing Particles

The following process is used to make drug-containing particles ofoxcarbazepine. The following ingredients in the amounts indicated areused.

AMT AMT AMT AMT AMT AMT (% WT.) (% WT.) (% WT.) (% WT.) (% WT.) (% WT.)INGREDIENT 1 2 3 4 5 6 Oxcarbazpine 67.5 67.8 65-70 65-70 66.7 65.2Microcrystalline 22.5 22.6 21-24 21.7-23.3 22.2 21.7 celluloseHydroxypropyl- 3.8 3.8 2.5-5   2.6-5   2.6 4.8 cellulose Sodium lauryl2.8 1.4 1-5 1.4-4.2 4.1 4 sulfate Crosscarmellose 3.4 4.4 2.4-5  2.4-4.5 4.3 4.2 sodium

AMT AMT AMT AMT AMT AMT (% WT.) (% WT.) (% WT.) (% WT.) (% WT.) (% WT.)INGREDIENT 7 8 9 10 11 12 Oxcarbazpine 70 68.6 66.4 68 67 68.3Microcrystalline 23.3 22.9 22.2 22.7 22.3 22.8 cellulose Hydroxypropyl-2.7 2.7 4.9 2.6 4.9 5 cellulose Sodium lauryl 1.5 1.4 4.1 4.2 1.4 1.4sulfate Crosscarmellose 2.5 4.5 2.4 2.4 1.4 2.4 sodium

Material % (w/w) Amount per batch (g) Oxcarbazepine 67.5% 2295.0Microcrystalline cellulose (Avicel 22.5% 765.0 PH101, FMC)Croscarmellose sodium (Ac-Di-Sol 3.4% 115.6 SD-711, FMC) Sodium LaurylSulfate 2.8% 95.2 Hydroxypropyl cellulose (HPC-SL 3.8% 129.2 fine,Nisso)

The drug-containing particles are made by wet granulation at a scale of4 L to 200 L. The following equipment and operating parameters wereused.

Equipment Manufacturer Location Parameters High Shear GranulatorCollette Wommelgem, Bowl size = 25 L (GRAL 25) Belgium Mixer and chopperon low speed Binder (water) flow rate 95 mL/min Fluid Bed ProcessorVector Marion, IA 50 C. inlet temperature (FLM.3) ~40 cfm air flow Dryto LOD 1-2% Comil (197S) Quadro Waterloo, Ontario, 3000 rpm CanadaMultiple passes (050G, 016C, 018R)

All powders were weighed and added to the bowl of the high sheargranulator. The dry powder was mixed at low speed for 1 minute. With themixer and chopper on low speed, water was added at a rate of 95 mL/minfor a total of 1164 g water (25.5% of final wet weight). The granulatorwas stopped once during the process to scrape the bowl. The wetgranulation was dried in a fluid bed drier at 50° C. to an LOD of 1-2%.Using a Comil at 3000 rpm, the dried material was milled through aseries of screens to reduce the particle size to an acceptable range for3DP. The milling began through a 050G screen and ended through a 018Rscreen. For most batches, a pass was made through an intermediate screen(016C) to prevent blinding.

EXAMPLE 2 Determination of Crystallinity

A differential scanning calorimeter is used to determine the level ofcrystallinity of materials before and after inclusion in coatedparticles. The following process for the temperature ramping profile wasused.

1. Equilibrate at −10° C.;

2. Ramp 10° C./min to 70° C.;

3. Isothermal for 5 min;

4. Ramp 10° C./min to −20° C.;

5. Equilibrate at −20° C.;

6. Modulate ±0.8° C. every 60 s;

7. Isothermal for 2 min;

8. Ramp 5° C./min to 250° C.;

9. Ramp 5° C./min to −10° C.

EXAMPLE 3 Preparation of a Three-Dimensionally Printed OrodispersibleDosage Form

The following process is used to prepare a taste-maskedthree-dimensionally printed orodispersible dosage form comprising amatrix comprising bound drug-containing particles of oxcarbazepine. Theingredients for the printing fluid and the bulk powder are used in theamounts indicated below:

Printing fluid I-A Water (% wt) 85 Glycerin (% wt) 5 Ethanol (% wt) 5Tween 20 (% wt) 1 Sucralose (% wt) 2

Bulk powder: II-A II-B II-C II-D II-E OXC containing particles (% wt) 5560 65 75 80 Avicel PH101 (% wt) 4.5 4.5 4.5 4.5 4.5 Mannitol (% wt) 3328 23 13 8 Polyvinypyrrolidone (% wt) 7 7 7 7 7 Silica (% wt) 0.5 0.50.5 0.5 0.5 HPC SL (% wt) (hydroxypropylcellulose)

II-F II-G II-H OXC containing particles (% wt) 70 70 60 Avicel PH101 (%wt) 19.5 9.5 9.5 Mannitol (% wt) 0 10 20 Polyvinypyrrolidone (% wt) 1010 10 Silica (% wt) 0.5 0.5 0.5

II-L II-M II-N II-O II-P OXC containing particles (% wt) 70 70 70 60 60Avicel PH101 (% wt) 9.5 0 0 4.5 4.5 Mannitol (% wt) 13 19.5 22.5 28 28Polyvinypyrrolidone (% wt) 7 10 7 7 0 Silica (% wt) 0.5 0.5 0.5 0.5 0.5HPC SL (% wt) 0 0 0 0 7 (hydroxypropylcellulose)

II-Q II-R II-S II-T OXC containing particles (% wt) 63.5 63.5 63.5 63.5Avicel PH101 (% wt) 0 21 11.1 21 Mannitol (% wt) 36 15 24.9 9Polyvinypyrrolidone (% wt) 0 0 0 0 Silica (% wt) 0.5 0.5 0.5 0.5 HPC SL(% wt) 0 0 0 6 (hydroxypropylcellulose)

Any three dimensional printer equipment assembly, known or mentionedherein, can be used. An incremental layer of bulk powder ofpredetermined thickness is spread onto a prior layer of powder, andprinting fluid is applied to the incremental layer as droplets accordingto a predetermined saturation level, line spacing and printing fluidflowrate to bind the particles therein. This two step process iscompleted until a matrix comprising the target amount of printedincremental layers.

The following printing parameters are used on a Z-Corp lab scale printer(Model Z310). The printer is equipped with a HP-10 printhead and isoperated at a scan rate of droplet size of 30-60 μm and line spacing of450-600 μm. A solid print pattern is used throughout the dosage form.The specified combination of printing fluid formulation and bulk powderformulation is used. A layer thickness of 0.008 to 0.011 inches is used.A saturation of 90 to 116% is used. The printing fluid I-A is used. Manydifferent combinations of the drug-containing particles Nos. 1-12 andbulk powder formulations IIA through II-T are used.

The printed matrix is separated from loose unprinted powder and theprinted matrix is dried by any suitable means to reduce the amount ofsolvent and moisture to a desired level, thereby producing the final 3DPorodispersible dosage form.

The dispersion time, surface texture (smoothness) and hardness of thedosage form are then determined

EXAMPLE 4 Preparation of a Taste-Masked Three-Dimensionally PrintedOrodispersible Dosage Forms with Varying Architecture Among IncrementalLayers

The 3DP process described above is followed; however, it can beconducted in several different ways to prepare dosage forms of differentarchitecture varying in hardness and composition of incremental layers.The following processes provide a dosage form having greater hardness inthe upper and lower surfaces as compared to the hardness of the interiorportion of the dosage form. This tactic helps create sections within adosage form with different mechanical properties. This approach is usedto design dosage forms in which the composition of the top and bottomlayers is different from the middle layers. This design allows thedosage forms to have stronger top and bottom layers, thereby increasinghardness and reducing friability, and a large middle portion with lowerhardness, which enables the dosage form to disperse rapidly.

Method A:

In this process, the amount of binder deposited in different incrementallayers or within different predefined regions within the sameincremental layers is varied. The process of Example 3 is followed toprepare these dosage forms, except that the amount of binder, by way ofthe printing fluid, deposited onto the powder is varied among theincremental powder layers by using printing fluids differing inconcentration of binder.

Method B:

The process of Example 3 is followed to prepare these dosage forms,except that the amount of printing fluid deposited onto the powder isvaried among the incremental powder layers. The upper and lowerincremental layers receive a higher amount of printing fluid and theincremental layers of the middle portion receive a lower amount ofprinting fluid.

Method C:

In this process, the printing pattern, employed for the upper and lowerincremental layers of the dosage form, is a solid pattern (FIG. 3A). Theprinting pattern for the middle portion of incremental layers is a grayscale (FIG. 3B).

Method D:

In this process, the printing pattern, employed for the upper and lowerincremental layers of the dosage form, is a solid pattern (FIG. 3A). Theprinting pattern for the middle portion of incremental layers is anannular/hollow high saturation printing with no printing in the areasurrounded by the annulus (FIG. 3C).

Method E:

In this process, the printing pattern, employed for the upper and lowerincremental layers of the dosage form, is a solid pattern (FIG. 3A). Theprinting pattern for the middle portion of incremental layers is acombination of interior gray scale printing surrounded by an exteriorhigh saturation printing (FIG. 3D).

EXAMPLE 5 Characterization of Dosage Forms

The following procedures were used to characterize thethree-dimensionally printed solid porous orodispersible matrices.

Friability

The matrices are analyzed for their resistance to breaking using thetablet friability test (USP protocol <1216>). The test employs a VanKelfriabilator (model 45-2000, Varian, USA) equipped with a drum having thedimensions of 285 mm in diameter and 39 mm deep, which is rotated at 25rpm for 100 revolutions. A minimum number of 10 dosage forms are tumbledat each revolution by a curved projection that extends from the middleof the drum to the outer wall. Thus, at each turn the tablets are causedto roll or slide and fall about 130 mm onto the drum or each other. Allloose powder is removed from the tablets and they are weightedcollectively before and after the 100 revolutions.

Surface Texture

The matrices are inspected visually with or without the aid of amicroscope. The surface texture analyzed to determine if it is rough orsmooth and whether the edges of indicia on the upper surface and theedges of the perimeter of the dosage form are clean and sharp or roughand jagged.

The matrices exhibited smooth surfaces with clean and sharp edges.

Hardness

The matrices are analyzed for overall hardness as determined by a tabletbreaking force assay according to USP <127> (31^(st) edition) using a VK200 tablet hardness tester (Varian, US). The strength or hardness of thedosage forms is measured by a fracture test. A dosage form is centeredbetween the jaws of the tester and force is applied until the dosageform fractures. The load at fracture is returned in kiloponds (kp). Akilopond is a metric unit of force measurement with 1 kp beingequivalent to 9.807 Newtons. A minimum number of 6 dosage forms aretested.

The hardness of the dosage forms ranges from about 0.5 to about 5 kP orabout 1 to about 3 kP.

Dispersion Time

The matrices are analyzed for dispersion time in aqueous fluid asfollows using a Texture Analyzer (TA HP, Texture Technologies, US)equipped with a 5 Kg load cell and a 1.0 inch diameter acrylic probe(Stable Micro Systems). The dosage form is attached to the probe withdouble-sided adhesive tape. Under a constant 50 g force (Dor et al. inPharm. Dev. Technol. (2000), 5(4), 575-577; and El-Arini et al. inPharm. Dev. Technol. (2002), 7(3), 361-371), the dosage form is immersedin 3 ml of water at room temperature in a flat bottom aluminum weighboat. The dispersion time test was conducted using the followingparameters. A minimum of 5 dosage forms was tested.

Test mode Compression Pre-test speed (mm/sec) 5 Test speed (mm/sec) 8Post-test speed (mm/sec) 10 Target mode Force Force (g) 50 Hold time(sec) 15 Trigger type Auto (force) Trigger force (g) 5 Water volume (ml)3

The dispersion time observed for the dosage forms is about 10 sec orless or about 5 sec or less.

Bulk Density

The bulk density of the matrix is determined by measuring the weight ofa dosage form and dividing that value by the calculated volume of thedosage form. The volume of a dosage form is calculated by measuring itsdimensions and using the proper mathematical formula according to theshape of the dosage form. For example, for a cylindrical dosage form,the volume of which is calculated using the form π*r²*H, wherein r isthe radius of the water and H is its height. A dosage form weighing 0.5g, having a height of 0.6 cm and a diameter of 1.1 cm, has a volume ofabout 0.57 cm³, and a bulk density of about 0.877 g/cm³, which isequivalent to about 877 mg/ml.

Dissolution of OXC

Dissolution testing is conducted according to the Guidance for Industry(Section 3.3.2; Waiver of In Vivo Bioavailability and BioequivalenceStudies for Immediate-Release Solid Oral Dosage Forms Based on aBiopharmaceutics Classification System. August 2000. Section IIIc, p 7).The method of USP <711> was followed. Dissolution is performed using aUSP Apparatus II (paddle) at 50 rpm using 900 mL of the followingdeaerated dissolution media: (1) 0.1N HCl; (2) 0.05 M sodium acetate, pH4.5 buffer and (3) 0.05M KH₂PO₄, pH 6.8 buffer at 37° C.

EXAMPLE 6 In Vivo Evaluation of Three-Dimensionally PrintedOrodispersible Dosage Forms

This method is used to establish efficacy of the dosage form. Singledosage forms comprising oxcarbazepine are administered twice daily to asubject at 12-hour intervals. Administration is done by placing thedosage form in the mouth of the subject and optionally administering asip (5-20 ml) of fluid to the subject. Within a short period of time,the dosage form disperses in the subject's mouth. Alternatively, thedosage form is dispersed in a minimal amount of fluid and thenadministered to the subject orally. The total daily dose ofoxcarbazepine will typically range from about 300 to 1200 mg. Thesubject's pharmacokinetic profile is determined using known methods inthe art. The subject level of therapeutic response to the dosage form isdetermined using known methods in the art.

EXAMPLE 7 Preparation of Three-Dimensionally Printed Rapidly DispersibleDosage Forms

The 3DP process described above is used to prepare a three-dimensionallyprinted rapidly dispersible dosage form comprising a matrix comprisingbound drug-containing particles of oxcarbazepine. The ingredients forthe printing fluid and the bulk powder are used in the amounts indicatedbelow.

Printing fluid III-A III-B Water (% wt)  80-95 80-90 Glycerin (% wt)0.5-20 2-7 Alcohol (% wt) 0.1-20  1-10 Tween 20 (% wt) 0.01-10  1-5Sucralose (% wt)   0-10 1-5 Binder (% wt)   0-10

Drug-containing particles: IV-A IV-B OXC (% wt) 55-75  60-70 AvicelPH101 (% wt) 15-35  20-30 HPC (% wt) 0-10 2-5 Surfactant (% wt) 0-10 1-5Croscarmellose (% wt) 0-10 >0-5 

Bulk powder: V-A V-B OXC containing particles (% wt) 55-65 55-65 AvicelPH101 (% wt)  2-15  3-12 HPC (% wt)  0-10  0-10 Mannitol (% wt) 15-4020-35 Polyvinypyrrolidone (% wt)  0-10  5-10 Silica (% wt) 0.1-1.50.2-0.7

The printing fluid is applied to incremental layers of bulk powder byway of a 3DP process to prepare a three-dimensionally printedorodispersible dosage form comprising a matrix comprising bounddrug-containing particles of OXC.

Final composition VII-A VII-B Oxcarbazepine (% wt) 30-40 35-45Microcrystalline cellulose (% wt) 15-30 15-25 Croscarmellose (% wt) 1-51-3 Mannitol (% wt) 10-30 15-30 PVP(% wt)  0-10  0-10 HPC (% wt)  0-12 0-10 Colloidal silicon dioxide (% wt) 0-2 0-2 Glycerin (%wt) >0-20 >0-5  Surfactant (% wt) 0-5 >0-5  Sweetener (% wt) 0-5 >0-5 

As used herein, the term “about” or “approximately” are taken tomean±10%, ±5%, ±2.5% or ±1% of a specified valued. As used herein, theterm “substantially” is taken to mean “to a large degree” or “at least amajority of or “more than 50% of”.

The above is a detailed description of particular embodiments of theinvention. It will be appreciated that, although specific embodiments ofthe invention have been described herein for purposes of illustration,various modifications may be made without departing from the spirit andscope of the invention. Accordingly, the invention is not limited exceptas by the appended claims. All of the embodiments disclosed and claimedherein can be made and executed without undue experimentation in lightof the present disclosure.

1) (canceled) 2) (canceled) 3) (canceled) 4) (canceled) 5) (canceled) 6)(canceled) 7) (canceled) 8) (canceled) 9) (canceled) 10) (canceled) 11)(canceled) 12) (canceled) 13) (canceled) 14) (canceled) 15) A rapidlydispersible porous non-compressed three-dimensionally printed boundmatrix comprising: drug-containing particles comprising at least onefirst disintegrant, at least one first binder, at least one surfactantand native particles of drug, wherein the drug-containing particles havean average, mean or median effective particle size and the nativeparticles of drug have an average, mean or median native particle size,and the ratio of average, mean or median effective particle size toaverage, mean or median, respectively, native particle size ranges fromgreater than 1:1 to 200:1; at least one second disintegrant; and atleast one second binder; wherein the hardness of the matrix ranges fromabout 1 to about 7 kiloponds. 16) The matrix of claim 15, wherein thematrix disperses in 15 sec or less when placed in 15 ml of aqueousfluid. 17) The matrix of claim 15, wherein the average native particlesize is such that 90%-100% wt of the drug is <10 microns, and the ratioof average effective particle size to average native particle size is inthe range of 10:1 to 200:1. 18) The matrix of claim 15, wherein theaverage native particle size is such that not more than 20% wt of thedrug is <32 microns, 40-70% wt of the drug is <63 microns, 70-95% wt ofthe drug is <125 microns, and 100% wt of the drug is <250 microns, andthe ratio of average effective particle size to average native particlesize is in the range of greater than 1:1 to about 10:1. 19) The matrixof claim 15, wherein the native particles of drug have an average, meanor median native particle size in the range of about 1 to about 90microns. 20) The matrix of claim 15, wherein the drug-containingparticles have an average, mean or median effective particle size in therange of about 50 to about 400 microns. 21) The matrix of claim 15,wherein the drug is a poorly water soluble. 22) The matrix of claim 21,wherein the drug is OXC. 23) The matrix of claim 15, comprising:drug-containing particles comprising at least one first disintegrant, atleast one first binder, at least one surfactant, a first grade of nativeparticles of drug and a second grade of native particles of drug,wherein the drug-containing particles have an average, mean or medianeffective particle size and the first grade of native particles of drughave an average, mean or median first native particle size and thesecond grade of native particles of drug have an average, mean or mediansecond native particle size, and the ratio of average, mean or medianeffective particle size to average, mean or median, respectively, firstnative particle size ranges from greater than 1:1 to about 5:1, and theratio of average, mean or median effective particle size to average,mean or median, respectively, second native particle size ranges fromabout 20:1 to about 50:1; at least one second disintegrant; and at leastone second binder; wherein the hardness of the matrix ranges from about1 to about 7 kiloponds. 24) The matrix of claim 23, wherein: thedrug-containing particles further comprise at least one sweetener and atleast one glidant; the matrix comprises particles bound by said secondbinder; the matrix disperses in less than 15 sec in a volume of 15 ml ofaqueous fluid; and/or the content of drug in the matrix is 35-60% wtbased upon the total weight of the matrix. 25) The matrix of claim 24,wherein: a) the at least one surfactant is present in an amount of0.5-7.0% wt based upon the final weight of the dosage form; b) the atleast one sweetener is present in an amount of 0.01-2.0% wt based uponthe final weight of the dosage form; c) the at least one first binderand the at least one second binder are together present in an amount of5-15% wt based upon the final weight of the dosage form; d) the at leastone first disintegrant and the at least one second disintegrant aretogether present in an amount of 10-30% wt based upon the final weightof the dosage form; and/or e) the at least one glidant is present in anamount of 0-2% wt based upon the final weight of the dosage form. 26)The matrix of claim 15, wherein: a) the native particles of drug possessa bi-modal or multi-modal particle size distribution; b) thedrug-containing particles possess a mono-modal, bi-modal or multi-modalparticle size distribution; or c) a combination of one or more of theabove. 27) The matrix of claim 15, wherein: a) the hardness ranges fromabout 1 to about 3 kp; b) the matrix disperses in 10 sec or less whenplaced in 15 ml of water or in saliva; c) the matrix comprises about 150mg to about 600 mg of drug; and/or d) the matrix comprises 10 to 40three-dimensionally printed incremental layers. 28) (canceled) 29) Thematrix of claim 15, wherein: a) the content of drug-containing particlesin the matrix is 55-85% wt based upon the total weight of matrix in thefinal dosage form; b) the content of native particles of drug in thedrug-containing particles is 55-85% wt based upon the final weight ofthe drug-containing particles; c) the content of first disintegrant inthe drug-containing particles ranges up to 30% wt, based upon the finalweight of the drug-containing particles; d) the content of first binderin the drug-containing particles ranges up to 10% wt, based upon thefinal weight of the drug-containing particles; e) the content ofsurfactant in the drug-containing particles ranges up to 10% wt, basedupon the final weight of the drug-containing particles; and/or f) thedrug-containing particles are manufactured by wet granulation. 30) Thematrix of claim 15, wherein the matrix comprises about 150 to about 1200mg of drug. 31) The matrix of claim 15, wherein the matrix has beenprepared by a three-dimensional printing process employing printingfluid, drug-containing particles and bulk powder of the followingcompositions: printing fluid comprising glycerin; drug-containingparticles comprising a first grade of drug native particles, the atleast one first disintegrant, the at least one first binder and at leastone first surfactant; and bulk powder comprising the drug-containingparticles, the at least one second disintegrant, the at least one secondbinder and at least one glidant. 32) The matrix of claim 31, wherein theprinting fluid comprises: a) glycerin and alcohol; or b) alcohol. 33)(canceled) 34) The matrix of claim 31, wherein: the printing fluidcomprises water, glycerin, alcohol and surfactant. 35) The matrix ofclaim 31, wherein the matrix has been prepared by a three-dimensionalprinting process employing printing fluid, drug-containing particles andbulk powder of the following compositions: Printing fluid Water (% wt) 80-95 Glycerin (% wt) 0.5-20 Alcohol (% wt) 0.1-20 Surfactant (% wt)0.01-10  Sweetener (% wt)   0-10 Binder (% wt)   0-10

Drug-containing particles: Drug (% wt) 55-75 Disintegrant (% wt) 15-45Binder (% wt)  0-10 Surfactant (% wt)  0-10

Bulk powder: Drug containing particles (% wt) 55-65 Disintegrant (% wt) 2-15 Binder (% wt) 20-45 Glidant (% wt) 0.1-1.5

36) The matrix of claim 15, wherein the matrix is shaped as a wafer,cylinder, ring, donut, tube, cube, spheroid, ellipsoid or rectangularbox. 37) The matrix of claim 15, wherein: a) the first binder and secondbinder are independently selected at each occurrence from the groupconsisting of polyvinylpyrrolidone, mannitol, hydroxypropylcellulose,and a combination thereof; b) the first disintegrant and the seconddisintegrant are independently selected at each occurrence from thegroup consisting of microcrystalline cellulose, a combination of twogrades of microcrystalline cellulose, croscarmellose, and a combinationthereof; or c) a combination of the above. 38) A method of treating adisease, condition or disorder that is therapeutically responsive to thedrug comprising administering the matrix of claim 15 one or more timesdaily to a subject in need thereof throughout a treatment period. 39)The matrix of claim 15, wherein the thickness of an incremental layerranges from 0.006 inches to 0.014 inches. 40) A three-dimensionallyprinted bound matrix comprising: drug-containing particles comprising atleast one first binder and native particles of drug, wherein thedrug-containing particles have an average, mean or median effectiveparticle size and the native particles of drug have an average, mean ormedian native particle size, and the ratio of average, mean or medianeffective particle size to average, mean or median, respectively, nativeparticle size ranges from greater than 1:1 to 200:1. 41) The matrix ofclaim 40, wherein: the drug-containing particles comprise at least onefirst binder, a first grade of native particles of drug and a secondgrade of native particles of drug, wherein the first grade of nativeparticles of drug have an average, mean or median first native particlesize and the second grade of native particles of drug have an average,mean or median second native particle size, and the average, mean ormedian first native particle size is smaller than the average, mean ormedian, respectively, second native particle size. 42) The matrix ofclaim 41, wherein: the drug-containing particles comprise at least onefirst binder, a first grade of native particles of drug and a secondgrade of native particles of drug, wherein the drug-containing particleshave an average, mean or median effective particle size and the firstgrade of native particles of drug have an average, mean or median firstnative particle size and the second grade of native particles of drughave an average, mean or median second native particle size, and theratio of average, mean or median effective particle size to average,mean or median, respectively, first native particle size ranges fromgreater than 1:1 to about 5:1, and the ratio of average, mean or medianeffective particle size to average, mean or median, respectively, secondnative particle size ranges from about 20:1 to about 50:1. 43) Thematrix of claim 40, wherein the bound matrix further comprises at leastone second binder that binds the drug-containing particles to form thebound matrix. 44) The matrix of claim 40, wherein the drug-containingparticles further comprise at least one first disintegrant. 45) Thematrix of claim 40, wherein the bound matrix further comprises at leastone second disintegrant outside the drug-containing particles. 46) Thematrix of claim 40, wherein the drug-containing particles are preparedby wet granulation. 47) The matrix of claim 15, wherein: a) thedrug-containing particles comprise at least two first disintegrants andat least one binder; b) the matrix comprises at least two second bindersand at least one second disintegrant; c) a combination of any of theabove. 48) The matrix of claim 15, wherein: a) at least one first binderis different than the at least one second binder; b) at least one firstdisintegrant is different than the at least one second disintegrant; c)at least one first binder is the same as the at least one second binder;d) at least one first disintegrant is the same as the at least onesecond disintegrant; or e) a combination of any of the above.